Literature DB >> 23503838

Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance.

Takuya Kuwashiro1, Toshihiko Mizuta, Yasunori Kawaguchi, Shinji Iwane, Hirokazu Takahashi, Noriko Oza, Satoshi Oeda, Hiroshi Isoda, Yuichiro Eguchi, Iwata Ozaki, Keizo Anzai, Kazuma Fujimoto.   

Abstract

BACKGROUND: Although it has been reported that hepatitis C virus (HCV) infection is associated with a significant decline in health-related quality of life (HRQOL), the underlying causes and mechanisms are still unknown. Insulin resistance (IR) is recognized as a distinct aspect of chronic HCV infection. Therefore, we attempted to identify the factors including IR indices that are related to the HRQOL of patients with chronic hepatitis C (CHC).
METHODS: One hundred and seventy-five CHC patients (91 female, 84 male, mean age, 56.4 years) not using antidiabetic agents were included and underwent a 75-g oral glucose tolerance test (OGTT) and completed a self-administered HRQOL questionnaire, the Short Form 36 (SF-36), which is a well-validated questionnaire for assessing general QOL. Scale scores were standardized and summarized into physical and mental component summary (PCS and MCS). We investigated which clinical parameters, including homeostasis model assessment of insulin resistance (HOMA-IR), were associated with decline in PCS and MCS scores in CHC patients.
RESULTS: There were no significant differences in clinical parameters between high and low MCS, but there were significant differences in age, sex, hemoglobin, liver fibrosis, OGTT pattern, and HOMA-IR between high and low PCS. Multivariate analysis showed that HOMA-IR >2 was independently associated with lower PCS (OR 2.92, p < 0.01).
CONCLUSIONS: Our results suggest that impairment of HRQOL, especially physical domains, in CHC patients is associated with IR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503838     DOI: 10.1007/s00535-013-0781-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  39 in total

1.  Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

Authors:  Hari S Conjeevaram; Abdus S Wahed; Nezam Afdhal; Charles D Howell; James E Everhart; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

2.  Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

Authors:  H L Bonkovsky; J M Woolley
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

Authors:  J E Ware; B Gandek
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0.

Authors:  I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

5.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

6.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

Review 7.  Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment.

Authors:  Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

8.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Christina A Meyers; Maher Albitar; Elihu Estey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

9.  Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

Authors:  J M Petit; J B Bour; C Galland-Jos; A Minello; B Verges; M Guiguet; J M Brun; P Hillon
Journal:  J Hepatol       Date:  2001-08       Impact factor: 25.083

10.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

View more
  4 in total

Review 1.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.

Authors:  Megumi Kawakubo; Yuichiro Eguchi; Michiaki Okada; Shinji Iwane; Satoshi Oeda; Taiga Otsuka; Syunya Nakashita; Norimasa Araki; Akemi Koga
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

Review 3.  Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?

Authors:  Tr Lim
Journal:  Hepat Med       Date:  2014-12-03

4.  Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.

Authors:  Sabrina Cossais; Michaël Schwarzinger; Stanislas Pol; Hélène Fontaine; Dominique Larrey; Georges-Philippe Pageaux; Valérie Canva; Philippe Mathurin; Yazdan Yazdanpanah; Sylvie Deuffic-Burban
Journal:  PLoS One       Date:  2019-05-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.